"The U.S. Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting). Perjeta is the first FDA-ap"...
- ABRAXANE should not be used in patients who have baseline neutrophil counts of < 1,500 cells/mm³.
- Patients who experience a severe hypersensitivity reaction to ABRAXANE should not be rechallenged with the drug.
Last reviewed on RxList: 8/17/2015
Additional Abraxane Information
Abraxane - User Reviews
Abraxane User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find support and advances in treatment.